Janssen IDViewpoints Janssen Pharmaceutical Companies of Johnson & Johnson

Antimicrobial Resistance - or AMR - is a term most people have likely heard, but few actually know the extent of the deadly threat it poses. Recent reports show that AMR now results in an estimated 700,000 deaths annually, worldwide and is predicted to increase to over 10 million annually by 2050 – surpassing predictions of annual deaths for cancer (8.2 million) and diabetes (1.5 million). Data also shows that the COVID-19 pandemic may have accelerated the threat of AMR, due to the many hospital admissions of patients with COVID-19 symptoms who are then treated with antibiotics to reduce chances of contracting secondary bacterial infections, increasing the commonality of resistant bacteria.  
Tune in as Jan Poolman, Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Dr. Steffanie Strathdee, Distinguished Professor, UC San Diego Department of Medicine, Co-Director, Center for Innovative Phage Applications and Therapeutics and author of The Perfect Predator discuss the potential threats that AMR can pose, and what a potential global action plan to protect against AMR would look like.

COVID-19 has certainly been the pressing respiratory topic over the last year, but as temperatures begin to drop, the school season gears up, and adults begin to re-enter the workforce, there are two seasonal infections making their way back: respiratory syncytial viruses (RSV) and influenza (flu). While experts generally know what to expect, this year may prove unique. For instance, there was an unusually low level of flu activity reported during the 2020-21 season – which experts are attributing to the measures we took to fight the COVID-19 pandemic. The reduced incidence suggests low levels of exposure to RSV or flu with people now likely to have waning levels of immunity to these viruses. We saw this summer that there was a notable uptick in incidence of RSV, indicating a delayed RSV season, probably as a result of relaxing the pandemic-related social distancing and other measures. These factors collectively contribute to an uncertain winter, with a potentially higher incidence of RSV and flu, leading to more severe symptoms/outcomes from these viruses.
Tune in as Hanneke Schuitemaker, Ph.D., Head of Viral Vaccine Discovery and Translational Medicine and Disease Area Stronghold Leader, Viral Vaccines, Janssen Vaccines & Prevention B.V. and Ann Falsey, M.D., Professor of Medicine at the University Of Rochester School Of Medicine discuss the outlook of the upcoming flu and RSV season, and precautions for high-risk populations such as young children and older adults, as we continue to adjust, worldwide, to the unforeseen outcomes of the COVID-19 pandemic.
The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your healthcare provider.
 

The COVID-19 crisis has dealt an inconceivable impact to the capacity of health systems and frontline workers and their ability to deliver essential health services. The demand for care in year one of the pandemic for COVID-19 patients was like nothing the world had seen, leaving frontline workers facing the significantly heightened importance of maintaining both preventative and curative services, especially for vulnerable populations such as children, the elderly, people living with chronic conditions and disabilities, and minorities. As we progress through the second full year of the pandemic, frontline workers are feeling no decline in the demand for care, as the community faces new challenges such as COVID-19 variants and vaccine supply issues. Tune in as Avrum “Avi” Spira, M.D., MSC, Global Head, Lung Cancer Initiative, Johnson & Johnson and John Ly, Advisor and Former Medical Director, Last Mile Health; Hospitalist, Assistant Clinical Professor, and Associate Program Director for Med-Peds Residency at the UCLA Medical Center in Los Angeles, California, discuss the impact of managing one entire year in a pandemic and best practices to implement in year two, as more people look to get vaccinated.
The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your doctor.

Before COVID-19, AIDS was one of the most pressing global health threats we faced.
In June 1981, the U.S. Centers for Disease Control and Prevention (CDC) published the first medical report regarding a deadly new syndrome affecting gay men in Los Angeles. These were the first reported cases of what would become known as AIDS. In the 1980s, an AIDS diagnosis was considered a death sentence, and the concept of people with HIV living long, healthy, and productive lives was virtually inconceivable.
Now, 40 years later, much of this has changed.
Thanks to the efforts of people at every level of the global HIV community, the inspiring passion of advocates everywhere, and the miracles of modern science, HIV has been transformed for many patients from a terminal illness into a chronic, manageable condition. But even with this progress, there are still significant global challenges. Each year, 1.7 million people acquire HIV, a disproportionate number of whom belong to vulnerable and underserved communities worldwide, and many more still struggle to access crucial prevention and treatment services.
Tune in as Dr. Brian Woodfall, Global Head Development, ID, Janssen Infectious Diseases & Vaccines, and Glenda E. Gray, President, and CEO of the South African Medical Research Council (SAMRC), Co-chair of Janssen’s Imbokodo study, and Co-chair of the South African arm of Janssen’s ENSEMBLE study, discuss the evolution of HIV, the challenges we still face and what we have to look forward to as the world marks 40 years of HIV.
The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your doctor.

After a year-long fight to find safe and effective solutions to help address COVID-19, government officials and healthcare communities worldwide have finally begun rolling out COVID-19 vaccines to ensure they are available to the people that need them most. Despite these rollouts, and the heightened importance of prioritizing vaccinations now more than ever in order to help end the global pandemic, surveys are showing that younger individuals are significantly less likely to get vaccinated compared to older generations, due to distrust in the speed of the approval process, ‘invincible syndrome,’ and feeling impervious to harm, as well as miseducation. Tune in as Pierre R. Theodore, MD, VP, Global Surgery Medical Affairs, J&J Global Public Health, and Cedric ‘Jamie’ Rutland, MD, certified Pulmonologist and National Spokesperson for the American Lung Association, discuss best practices for reaching and educating hesitant individuals among younger generations on vaccine education to boost vaccine confidence.
The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your doctor.

As the response to the COVID-19 pandemic continues, we explore the importance of containing, managing, and preventing infectious disease outbreaks, particularly Ebola in the Democratic Republic of Congo (DRC). We look at what it means to engage communities, build partnerships, and use science to help prevent infectious disease outbreaks from reaching epidemic status. Dr. Macaya Douoguih, Head of Clinical Development and Medical Affairs, Vaccines at the Janssen Pharmaceutical Companies of Johnson & Johnson, and Dr. Daniel Bausch, Professor at the London School of Hygiene and Tropical Medicine and Director of the UK Public Health Rapid Support Team, will discuss the importance of global health security.
 
The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your doctor.